A new recipe is not just a list of ingredients for Development to approve. It changes what the factory receives, handles, cleans, packs and labels. Even when no new allergen is deliberately added, a supplier switch or change in physical form can alter cross-contact routes. Waiting until the first routine run to discover that the existing schedule or cleaning method no longer fits creates exposure before the control has been designed.
Allergen assessment belongs early in product and process change. It needs reliable material information, a view of how the changed product will move through the actual factory, and decisions from the teams that control equipment, cleaning, packaging and release. The aim is to make the proposed product and the manufacturing arrangement agree before introduction, then check that the arrangement works in use.
Assess intentional allergens and cross-contact separately
The first question is which allergens are intentionally present in the product as formulated. Ingredient composition, processing aids, compound ingredients and supplier information can all affect that answer. The finished-product specification and consumer information should represent the approved product. A changed ingredient name or supplier code is not sufficient evidence that the allergen profile is unchanged.
The second question is how allergen material could reach a product in which it is not intended. Routes may include shared equipment, airborne dust, utensils, rework, storage, handling or a changeover sequence. This is a cross-contact question, not a second version of the ingredient list. A product can have unchanged intentional allergens while its exposure to another allergen changes because the new material behaves differently on the line.
Consider replacing a liquid ingredient with a powdered alternative that has the same declared allergen content. Powder handling may create dust, deposit material in a different part of the room or be harder to remove from shared equipment. The formulation question might be unchanged, but the pathway and cleaning questions are new. The actual response depends on the ingredient, environment and process.
Keeping the two questions separate helps avoid opposite errors. A site should not overlook cross-contact because the recipe adds no new allergen, nor should it treat every theoretical route as proof that the product contains that allergen. Assessment needs evidence about materials, physical state, equipment, movement and existing controls.
Bring reliable material facts into the change decision
Supplier and material information must be current enough to support the intended use. Review the specification, allergen content, relevant cross-contact information, handling needs and any change notification. For compound materials, the site may need to understand sub-ingredients and the basis of supplier statements. A previous material approval does not automatically cover a new source, manufacturing site or physical form.
Development, Procurement and Technical should agree which facts are needed before the factory trial or launch. Where information is incomplete, the gap should remain a decision constraint. Guessing from a familiar product name or copying a previous allergen matrix can misstate both intentional content and cross-contact exposure. The site may need to obtain clarification, restrict the trial or defer approval while the evidence is gathered.
Material identity also has to survive into receiving and production. The approved code, supplier, specification and any segregation requirement should align with purchasing, intake and recipe controls. A technically correct assessment that cannot be linked to the actual delivered material will not prevent a substitution on the line. Change control should define what variation is allowed and who can authorise an alternative.
The review should also say when a supplier statement needs more context. A broad “may contain” declaration, for example, may describe conditions at the supplier's site without explaining the material's actual route through the receiving factory. Conversely, a material described as free from a named allergen does not address exposure created by shared factory equipment after intake. Supplier evidence and site assessment answer different parts of the problem. Where the supplier changes its process or source, the site should decide whether the earlier cross-contact assumptions still hold before relying on the same handling plan.
Trace material movement and cross-contact routes through the factory
An allergen assessment should follow the material from delivery to finished pack. Where is it stored, weighed, opened, transferred and added? Which surfaces, people, containers or air movements could carry residue? Which products share equipment or rooms before and after it? The answers should reflect actual routes and operating conditions, including start-up, rework and cleaning, rather than a generic floor plan.
Controls may include physical or time segregation, dedicated or identified utensils, contained handling, protective clothing, scheduling and defined waste or spill response where relevant. Each should address a particular pathway. A red tool or a separate shelf does little if powder spreads through an uncontained transfer step; a clever sequence does little if rework is returned to an incompatible product. The control set should be designed as a system, not as a list of familiar precautions.
Scheduling needs particular attention when a new product enters a shared line. An allergen-to-non-allergen changeover may need a supported cleaning method and verification before the next product starts. If the revised recipe changes soil load or where residue accumulates, the previous cleaning validation basis may need review. Routine verification of a completed clean is important, but a favourable swab at one location cannot alone prove that an altered method is capable across all relevant surfaces and conditions.
Rework and work in progress are easy to miss during a development change. A trial batch may be identifiable while routine rework bins, part-used ingredients or returned product follow older rules. The change plan should explain what can be reintroduced, into which product, and how identity and status are preserved. For a new allergen profile, the old rework route may no longer be acceptable even when the main production schedule has been updated.
Align specification, label and release before launch
The finished-product definition, recipe, pack artwork and line instructions must describe the same authorised product. When the allergen assessment changes intentional content or supported consumer information, specification and label review should precede production with that pack. When cross-contact controls change without a declaration change, the operational documents and release evidence still need updating. A decision on precautionary information should follow the relevant assessment and market requirements; it is not an automatic substitute for avoidable factory cross-contact.
Packaging control is a physical hand-off. The right artwork can be approved in a system while an old version remains at the packing line. The launch plan should identify which packs are permitted, what obsolete stock must be blocked, and how first-run checks confirm the pack applied to the actual product. A label check is protective but cannot repair a poor cleaning sequence or inaccurate supplier data upstream.
Release criteria should reflect the change. The site may need evidence of approved material, completed changeover, correct pack, process conditions and any relevant verification or trial results. The responsible person must know which gaps prevent release and who can resolve them. Final testing may contribute evidence, but negative results from a limited sample do not replace the material, segregation and cleaning controls that should prevent exposure in the first place.
Plan trials to test readiness and protect later products
A factory trial can reveal whether a new product is manufacturable under the proposed controls. It should have a defined purpose, bounded materials and product status, clear cleaning and packaging arrangements, and an authorised decision on what happens to trial output. If a trial is needed to validate process or cleaning capability, the questions and evidence should be planned before it starts. “We will see how it goes” is not a sufficient basis for exposing later products to a new allergen route.
Trial observations should feed back into the assessment. A powder may disperse further than expected; a piece of equipment may retain residue; an intended changeover may take longer than the planned window. Those findings can require a different method, equipment modification, schedule or product/pack decision. The routine launch should wait until the relevant issues are resolved or a justified, authorised arrangement is in place.
The first routine run still needs attention. Check that material identity, segregation, cleaning, rework, line instructions, artwork and release evidence are used as approved. Subsequent verification may be needed to show the arrangement remains effective across shifts or normal operating variation. Launch approval is a decision to use a defined control state, not proof that every future execution will be correct.
Review allergen impact when materials, equipment, sequence or packaging change
Change can begin outside Development. Procurement may propose a new supplier, Engineering may alter equipment, Production may adjust sequencing, or Packaging may change a component. Each route should prompt allergen impact review before the altered arrangement becomes routine. The trigger is a potential change in material facts or cross-contact pathway, not only the addition of a named allergen to a recipe.
A practical test is to trace one proposed change from its first request to the first released batch. Can the site show what was known about intentional content and cross-contact, which factory controls changed, who approved the product and pack, what the trial found, and how the line demonstrated readiness? If those answers are connected before introduction, allergen control has been built into the change. If they are assembled after launch, the factory has already taken the risk the review was meant to manage.
